Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Surrozen (NasdaqCM:SRZN) with a Buy ...

H.C. Wainwright maintained a Buy rating on Galiano Gold (NYSE:GAU) but reduced the price target to $2.80 from the previous $3.10. Trading at $1.17, the stock has seen a -32% return over the past six ...

H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared ...

H.C. Wainwright downgraded Cargo Therapeutics (CRGX) to Neutral from Buy without a price target The company’s FIRCE-1 trial was discontinued ...

HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a report released on Tuesday, ...

Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Immunocore in a research report issued to ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China ...